

DocGo Inc. (DCGO)


Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001822359

DocGo Inc. DCGO; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 28.6; sampling error 2.5 points; lower is stronger
Rank	107 of 371
Profitability	A percentile 6.8
Solvency	C/D percentile 59.1
Growth and financing	C/D percentile 57.9
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$217.1M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	late filer; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Mar 16, 2026 207 days before the rescans; latest periodic filing 10-Q received Aug 17, 2026
Last close	\$0.34 2026-10-08; market equity \$33.5M
Price used in grade	None



B, the elk
second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D from Mar 21, 2024, C/D from Dec 21, 2024, A from Mar 21,

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 16, 2026

DocGo is leading the proactive healthcare revolution. We are democratizing access with our innovative care delivery platform that includes mobile health services, virtual care management and ambulance services. Our goal is to deliver healthcare at any address and help reshape the traditional healthcare system, driven by our mission to bring high quality, highly accessible care to all. DocGo's proprietary technology platform, dedicated network of certified health professionals, including virtual care clinicians, and robust fleet

of medical response vehicles provide services in all 50 states and the United Kingdom.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 6.8						
Gross profitability		not computable	32.2%			latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(64.5%)	(6.6%)	6.8	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 59.1						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(4.05)	(0.31)	50.6	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		2.26x	2.96x	67.7	839	2025-12-31
Growth and financing, sleeve percentile 57.9						
Revenue growth, three-year compound		(9.9%)	10.0%	85.3	415	2025-12-31
Free cash flow growth, three-year compound		5.2%	10.9%	60.0	96	2025-12-31
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(18.0%)	2.1%	80.5	704	2025-12-31
Net share issuance, one year		(3.2%)	2.5%	5.7	634	2026-03-12


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Fortress balance sheet	cash minus debt is 50,783,074 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
102	Tela Bio, Inc. (TELA)	27.3	B	fortress balance sheet
103	Alphatec Holdings, Inc. (ATEC)	27.6	B	
104	Agape ATP Corp. (ATPC)	27.8	B	late filer
105	Agios Pharmaceuticals, Inc. (AGIO)	28.1	B	short runway
106	Myriad Genetics Inc. (MYGN)	28.4	B	fortress balance sheet
107	DocGo Inc. (DCGO) <	28.6	B	late filer, fortress balance sheet
108	Healthcare Services Group Inc. (HCSG)	28.9	B	
109	Staar Surgical Co. (STAA)	29.2	B	
110	Cytokinetics Inc. (CYTK)	29.5	B	short runway
111	Steris plc (STE)	29.7	B	
112	Cadre Holdings, Inc. (CDRE)	30.0	B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(72.0%)	8.0%	6
Distance from 52-week high	(77.3%)	(31.4%)	9
EBIT to enterprise value	(2,099.2%)	(1.5%)	0
Free cash flow yield	89.3%	(1.0%)	100
Book value to price	3.55	0.28	99
Sales to price	9.62	0.31	99
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(1.48)	(0.14)	6

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$25.2M
Operating cash flow, four quarters	-\$22.7M
Months of runway	13.3
Days since last periodic filing	53 (10-Q received Aug 17, 2026)
Median daily dollar volume, 63 sessions	\$251,323

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$440.5M	2022-12-31	2025-02-27	10-K	0001822359-25-000018
2	cost of revenue	us-gaap:CostOfRevenue	\$523.9M	2022-12-31	2023-03-14	10-K	0001213900-23-019936
3	assets	us-gaap:Assets	\$393.3M	2022-12-31	2025-02-27	10-K	0001822359-25-000018
4	operating income	us-gaap:OperatingIncomeLoss	-\$178.0M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$177.5M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$8.9M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
7	total debt	us-gaap:LongTermDebt	\$235,583	2025-12-31	2026-03-16	10-K	0001628280-26-018214
8	book equity	us-gaap:StockholdersEquity	\$144.0M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$51.0M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
10	total debt	us-gaap:LongTermDebt	\$17,730	2024-12-31	2025-02-27	10-K	0001822359-25-000018
11	book equity	us-gaap:StockholdersEquity	\$320.9M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$89.2M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
13	net income	us-gaap:NetIncomeLoss	-\$182.4M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$34.5M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
15	assets	us-gaap:Assets	\$217.1M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
16	assets	us-gaap:Assets	\$455.6M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
17	current assets	us-gaap:AssetsCurrent	\$152.4M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
18	current liabilities	us-gaap:LiabilitiesCurrent	\$67.5M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
19	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$183.8M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
20	liabilities	us-gaap:Liabilities	\$91.2M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
21	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$15.7M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
22	revenue	us-gaap:Revenues	\$322.2M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
23	revenue	us-gaap:Revenues	\$616.6M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
24	revenue	us-gaap:Revenues	\$624.3M	2023-12-31	2026-03-16	10-K	0001628280-26-018214
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.5M	2025-12-31	2026-03-16	10-K	0001628280-26-018214
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$70.1M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.6M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$64.5M	2023-12-31	2026-03-16	10-K	0001628280-26-018214
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.3M	2023-12-31	2026-03-16	10-K	0001628280-26-018214
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$28.9M	2022-12-31	2025-02-27	10-K	0001822359-25-000018
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.2M	2022-12-31	2025-02-27	10-K	0001822359-25-000018
32	current assets	us-gaap:AssetsCurrent	\$304.5M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
33	current liabilities	us-gaap:LiabilitiesCurrent	\$121.8M	2024-12-31	2026-03-16	10-K	0001628280-26-018214
34	assets	us-gaap:Assets	\$490.5M	2023-12-31	2026-03-16	10-K	0001628280-26-018214
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	98,750,251	2026-03-12	2026-03-16	10-K	0001628280-26-018214
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	101,982,549	2025-02-25	2025-02-27	10-K	0001822359-25-000018